Morgan Stanley Maintains Equal-Weight on Moderna, Raises Price Target to $95
Morgan Stanley analyst Terence Flynn maintains Moderna (NASDAQ:MRNA) with a Equal-Weight and raises the price target from $89 to $95.
Stocks · News reference
Moderna shares are trading lower, possibly as the stocks sells of from recent strength related to a suspected pneumonic plague in Russia.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Tempus Announces Expanded Collaboration With Merck And Moderna For Potential Commercialization Of Cancer Vaccine Intismeran Autogene; Terms Not Disclosed
Moderna, Vaxcyte and Novavax Are Trending After-Hours as Suspected Pneumonic Plague In Russia Stirs Anxiety
Vaccine stocks are trending on Tuesday. Shares of Moderna Inc. (NASDAQ:MRNA), Vaxcyte Inc. (NASDAQ:PCVX) and Novavax Inc. (NASDAQ:NVAX) are moving in the after-hours session on Monday. Moderna rose 0.17% to